Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract

J. M. Pogue, D. D. Depestel, D. R. Kaul, Yasser Khaled, D. G. Frame

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Oral vancomycin is often considered the drug of choice for severe Clostridium difficile-associated disease due to both its efficacy and pharmacokinetics. The potential for absorption is not well described in patients with impaired gastrointestinal (GI) mucosa. We describe a case of significant and potentially toxic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with grade IV graft-versus-host disease (GVHD) of the GI tract. In patients with GI GVHD clinicians need to be aware of the potential for oral absorption and, in select cases, monitoring of levels may be appropriate.

Original languageEnglish (US)
Pages (from-to)467-470
Number of pages4
JournalTransplant Infectious Disease
Volume11
Issue number5
DOIs
StatePublished - Oct 1 2009

Fingerprint

Graft vs Host Disease
Vancomycin
Gastrointestinal Tract
Transplants
Clostridium difficile
Poisons
Mucous Membrane
Pharmacokinetics
Pharmaceutical Preparations
Peripheral Blood Stem Cells
Physiological Absorption

All Science Journal Classification (ASJC) codes

  • Transplantation
  • Infectious Diseases

Cite this

Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. / Pogue, J. M.; Depestel, D. D.; Kaul, D. R.; Khaled, Yasser; Frame, D. G.

In: Transplant Infectious Disease, Vol. 11, No. 5, 01.10.2009, p. 467-470.

Research output: Contribution to journalArticle

@article{9c88ed84bba14eda948682e825559518,
title = "Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract",
abstract = "Oral vancomycin is often considered the drug of choice for severe Clostridium difficile-associated disease due to both its efficacy and pharmacokinetics. The potential for absorption is not well described in patients with impaired gastrointestinal (GI) mucosa. We describe a case of significant and potentially toxic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with grade IV graft-versus-host disease (GVHD) of the GI tract. In patients with GI GVHD clinicians need to be aware of the potential for oral absorption and, in select cases, monitoring of levels may be appropriate.",
author = "Pogue, {J. M.} and Depestel, {D. D.} and Kaul, {D. R.} and Yasser Khaled and Frame, {D. G.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1111/j.1399-3062.2009.00426.x",
language = "English (US)",
volume = "11",
pages = "467--470",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract

AU - Pogue, J. M.

AU - Depestel, D. D.

AU - Kaul, D. R.

AU - Khaled, Yasser

AU - Frame, D. G.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Oral vancomycin is often considered the drug of choice for severe Clostridium difficile-associated disease due to both its efficacy and pharmacokinetics. The potential for absorption is not well described in patients with impaired gastrointestinal (GI) mucosa. We describe a case of significant and potentially toxic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with grade IV graft-versus-host disease (GVHD) of the GI tract. In patients with GI GVHD clinicians need to be aware of the potential for oral absorption and, in select cases, monitoring of levels may be appropriate.

AB - Oral vancomycin is often considered the drug of choice for severe Clostridium difficile-associated disease due to both its efficacy and pharmacokinetics. The potential for absorption is not well described in patients with impaired gastrointestinal (GI) mucosa. We describe a case of significant and potentially toxic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with grade IV graft-versus-host disease (GVHD) of the GI tract. In patients with GI GVHD clinicians need to be aware of the potential for oral absorption and, in select cases, monitoring of levels may be appropriate.

UR - http://www.scopus.com/inward/record.url?scp=70349666859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349666859&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3062.2009.00426.x

DO - 10.1111/j.1399-3062.2009.00426.x

M3 - Article

VL - 11

SP - 467

EP - 470

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 5

ER -